Quipt Home Medical Corp. (QIPT Q1 FY2024 earnings call

Key Points

• Quipt's model is centered on clinical excellence and a patient-centric ecosystem with technology-enabled equipment solutions and specialized clinical respiratory programs.
• Approximately 80% of the product mix is dedicated to respiratory care.
• Fiscal Q1 2024 saw record revenue of $65.4 million, 60% YOY growth, and adjusted EBITDA of $15.3 million, 71% YOY growth.
• Recurring revenue was 83% of total revenue.
• Focus on expanding the continuum of care, cross-selling products, stable supply chain, and favorable regulatory landscape.
• Sleep segment unaffected by GLP-1 drugs, with CPAP/BiPAP remaining the gold standard for obstructive sleep apnea.
• Over 20 million Americans have undiagnosed OSA, representing potential market expansion.
• Regulatory stability with no competitive bidding signs and easing of home oxygen restrictions.
• Operational efficiency through automation, e-prescribing investments, and resupply program growth.

Approximately 80% of Quipt Home Medical's product mix is dedicated to respiratory care. In fiscal Q1 2024, the company recorded record revenue of $65.4 million, a 60% year-over-year growth. Adjusted EBITDA was $15.3 million, a 71% year-over-year increase. Recurring revenue base sat at 83% of total revenue. Customer base increased 56% year-over-year to 155,434 unique patients served. Unique setups and deliveries increased 47% to 215,370. Respiratory resupply setups deliveries were up 77% to 123,190. The resupply program serves 172,000 patients with a 72% growth rate, contributing to the recurring revenue mix.

Forward-Looking Statements

• Expect steady organic growth of 8% to 10% in fiscal 2024.
• Run rate revenue at $262 million and run rate adjusted EBITDA at $61 million.
• Anticipate 6% to 8% cash flow from operations after CapEx/lease payments.
• Resupply program is annualized at $106 million, contributing to recurring revenue.

Risks

• Ongoing DOJ investigation described as a fact-finding inquiry with no conclusion on wrongdoings yet. The company has strong internal controls on billing and compliance procedures in place and is confident in its practices.

Q: Could you say anything about the ongoing DOJ investigation?

A: It's an ongoing fact-finding inquiry by regulatory authorities. The government has not reached a conclusion on wrongdoings. We believe in strong internal controls on billing and compliance.

Q: How to increase e-prescribing penetration?

A: The challenge is physician adoption. We're working with sales teams and have initiatives like supplier-initiated orders to push prescription renewals to doctors.

Q: About resupply program and cash flow?

A: The resupply program has higher cash flow than some rental business but is part of a consolidated business with other operational elements.

Q: What instigated the DOJ investigation?

A: It's hard to determine exactly, but it's a broad fact-finding inquiry into billing claims.

Q: Seen similar industry cases?

A: It's not uncommon for DME companies to face such inquiries. Each case is unique, and the government hasn't concluded wrongdoing.

Q: When to expect updates on the DOJ investigation?

A: We will provide timely updates, possibly on a quarterly basis or through PRs as needed. It's not impacting operational M&A efforts at this stage.